Collectively, these findings suggest that targeting gp96/LFA-1 axis–mediated Treg infiltration into the TME is a powerful strategy to augment anti–PD-1 cancer immunotherapy by overcoming CD8+ T cell exhaustion without inducing autoimmune diseases. The gene discussed is PDCD1; the disease is cancer.